血清MCP-1、CXCL16与乳腺癌新辅助化疗效果和预后关系研究  

Relationship between serum MCP-1,CXCL16 and the efficacy of neoadjuvant chemotherapy and prognosis in breast cancer

作　　者：梁艳 张学良[2] 白晓蓉[1] 高晨[1] 董成芳 LIANG Yan;ZHANG Xueliang;BAI Xiaorong;GAO Chen;DONG Chengfang(Department of Breast Surgery,Gansu Provincial Cancer Hospital,Lanzhou 730000,China;Department of Medical Oncology,Gansu Provincial Cancer Hospital,Lanzhou 730000,China)

机构地区：[1]甘肃省肿瘤医院乳腺外科,甘肃兰州730000 [2]甘肃省肿瘤医院肿瘤内科,甘肃兰州730000

出　　处：《陕西医学杂志》2025年第5期645-648,共4页Shaanxi Medical Journal

基　　金：甘肃省卫生健康行业科研计划项目(GSWSKY2020-04)。

摘　　要：目的:探讨血清单核细胞趋化蛋白-1(MCP-1)、CXC趋化因子配体16(CXCL16)与乳腺癌新辅助化疗(NAC)效果和预后的关系。方法:选取乳腺癌患者125例,给予手术前NAC治疗,根据NAC疗效将患者分为病理完全缓解(pCR)组(31例)和非pCR组(94例)。术后随访5年,根据预后情况分为预后不良组(27例)和预后良好组(98例)。比较不同NAC疗效及预后患者血清MCP-1、CXCL16水平。采用Spearman法分析血清MCP-1、CXCL16水平与患者NAC疗效及预后的相关性。绘制受试者工作特征(ROC)曲线分析血清MCP-1、CXCL16对乳腺癌患者NAC疗效以及预后不良的预测价值。结果:非pCR组血清MCP-1、CXCL16水平高于pCR组(均P<0.05)。预后不良组血清MCP-1、CXCL16水平高于预后良好组(均P<0.05)。血清MCP-1、CXCL16水平与非pCR呈正相关,与预后不良呈正相关(均P<0.05)。血清MCP-1、CXCL16及两者联合预测乳腺癌患者NAC治疗后非pCR的曲线下面积(AUC)分别为0.824、0.842、0.942,且两者联合预测的AUC大于血清MCP-1、CXCL16单独预测的AUC(均P<0.05)。血清MCP-1、CXCL16及两者联合预测乳腺癌患者预后不良的AUC分别为0.710、0.779、0.864,且两者联合预测的AUC大于血清MCP-1单独预测的AUC(均P<0.05)。结论:血清MCP-1、CXCL16与乳腺癌NAC疗效和预后有关,且两者对患者NAC疗效及预后不良具有较高的预测价值。Objective:To investigate the relationship between serum monocyte chemoattractant protein-1(MCP-1),CXC chemokine ligand 16(CXCL16)and the efficacy of neoadjuvant chemotherapy(NAC)as well as prognosis in breast cancer.Methods:A total of 125 patients with breast cancer who received NAC before surgery were included.Patients were divided into the pathological complete response(pCR)group(31 cases)and non-pCR group(94 cases)based on the efficacy of NAC.After surgery,patients were followed up for 5 years and further divided into poor-prognosis group(27 cases)and good-prognosis group(98 cases)based on their prognosis.Serum levels of MCP-1 and CXCL16 were compared between different NAC efficacy and prognosis groups.Spearman correlation analysis was used to assess the correlation between serum MCP-1 and CXCL16 levels with NAC efficacy and prognosis.Receiver operating characteristic(ROC)curves were plotted to analyze the predictive value of serum MCP-1 and CXCL16 for NAC efficacy and poor prognosis in breast cancer patients.Results:Serum levels of MCP-1 and CXCL16 were higher in the non-pCR group compared to the pCR group(all P<0.05).Similarly,patients in the poor-prognosis group had higher serum levels of MCP-1 and CXCL16 compared to those in the good-prognosis group(all P<0.05).Serum MCP-1 and CXCL16 levels were positively correlated with non-pCR and poor prognosis(all P<0.05).The AUC for predicting non-pCR in breast cancer patients using serum MCP-1,CXCL16 and the combination of both were 0.824,0.842 and 0.942,respectively.The combined prediction had a higher AUC than individual predictors(all P<0.05).For predicting poor prognosis,the AUC values for serum MCP-1,CXCL16 and the combination were 0.710,0.779,and 0.864,respectively,with the combined prediction showing a higher AUC than serum MCP-1 alone(all P<0.05).Conclusion:Serum MCP-1 and CXCL16 levels are associated with the efficacy of NAC and prognosis in breast cancer patients,and both markers have high predictive value for the efficacy of NAC and poor prognosis.

关 键 词：乳腺癌 单核细胞趋化蛋白-1 CXC趋化因子配体16 新辅助化疗 预后 预测价值 

分 类 号：R737.9[医药卫生—肿瘤]